Lucie Arnaud

Ms. Lucie Arnaud

Université Clermont Auvergne, Clermont-Ferrand, Auvergne-Rhône-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
VWValérie Weber
Valérie Weber
LALucie Arnaud
Lucie Arnaud
SDSladjana Dukic-Stefanovic
Sladjana Dukic-Stefanovic
Barbara WenzelBarbara Wenzel
Barbara Wenzel
VRValérie Roux
Valérie Roux
AMAurélie Maisonial-Besset
Aurélie Maisonial-Besset
Isocitrate dehydrogenases (IDHs) are metabolic enzymes commonly mutated in human cancers (glioma, acute myeloid leukaemia, chondrosarcoma, and intrahepatic cholangiocarcinoma). These mutated variants of IDH (mIDH) acquire a neomorphic activity, namely, conversion of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate involved in tumourigenesis. Thus, mIDHs have emerged as highly promising therapeutic targets, and several mIDH specific inhibitors have been developed. However, the evaluation of mIDH status, currently performed by biopsy, is essential for patient stratification and thus treatment and follow-up. We report herein the development of new radioiodinated and radiofluorinated analogues of olutasidenib (FT-2102) as tools for noninvasive single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging of mIDH1 up- and dysregulation in tumours. Nonradiolabelled derivatives 2 and 3 halogenated at position 6 of the quinolinone scaffold were synthesised and tested in vitro for their inhibitory potencies and selectivities in comparison with the lead compound FT-2102. Using a common organotin precursor, (S)-[125I]2 and (S)-[18F]3 were efficiently synthesised by radio-iododemetallation and copper-mediated radiofluorination, respectively. Both radiotracers were stable at room temperature in saline or DPBS solution and at 37 °C in mouse serum, allowing future planning of their in vitro and in vivo evaluations in glioma and chondrosarcoma models.

28 October 2026 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Open access
PDF file
SKSarandeep Kaur
Sarandeep Kaur
SDSladjana Dukic‐Stefanovic
Sladjana Dukic‐Stefanovic
LALucie Arnaud
Lucie Arnaud
JCJean-Michel Chezal
Jean-Michel Chezal
Barbara WenzelBarbara Wenzel
Barbara Wenzel
AMAurélie Maisonial-Besset
Aurélie Maisonial-Besset
Isocitrate dehydrogenase 1/2 (IDH1/2) mutations are key oncogenic drivers in multiple cancers and represent important diagnostic and therapeutic targets, particularly in glioma and chondrosarcoma. Here, we report the design, synthesis, and in vitro evaluation of iodinated derivatives based on the tetrahydropyrazolopyridine scaffold of the mIDH1 inhibitors SK60 and SK87 . Structure‐guided modification of the halogenated benzyl moiety yielded iodinated analogues SK140 ( 9 ) and SK148 ( 10 ), which demonstrated nanomolar inhibitory potencies against IDH1R132C in vitro, exceeding that of the corresponding fluorinated compounds. Radiolabeling was successfully achieved using iodine‐125 via organotin precursors, affording [ 125 I]SK140 and [ 125 I]SK148 in good radiochemical yields. Both radiotracers exhibited excellent stability in formulation media (ethanol, 0.9% NaCl, and PBS) over 24 h at RT. Collectively, these results demonstrate that iodinated tetrahydropyrazolopyridine derivatives can be efficiently radiolabeled and remain stable under formulation conditions, supporting their further evaluation as potential mIDH1‐targeting radiotracers.